HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharmavite Diabetes Health Pack, Cholest-Off Claims Cited By FDA

This article was originally published in The Tan Sheet

Executive Summary

Labeling claims for Pharmavite's Diabetes Health Pack imply the product is "intended to meet the dietary needs of persons with diabetes," rendering it a drug, FDA states in a recent "courtesy" letter

You may also be interested in...



Pharmavite Diabetes Health Pack Slated For June Rollout

Pharmavite expects to begin shipping a dietary supplement combination pack tailored in June to meet the health needs of diabetics, the company said

COX-2 Inhibitor Structure/Function Claim Draws FDA “Courtesy” Letter

FDA cites pain relief and macular degeneration claims for two Vita Cube Systems dietary supplements in recent "courtesy" letters

Pharmavite Cholest-Off Claims Cited In FDA “Courtesy” Letter

Pharmavite expects to respond within the next few weeks to an FDA "courtesy" letter challenging claims for its Nature Made Cholest-Off dietary supplement

Related Content

Topics

UsernamePublicRestriction

Register

WI964826

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel